GHGuardant Health, Inc.
$167.39+183% 1Y
$167.39
$57.6752 weeks$187.33
The financials
Guardant Health, Inc. by the numbers
Guardant Health, Inc. (GH) reported revenue of $335M in Q2 2026 (quarter ended Jun 30, 2026), up 44% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $120M. For the full year FY2025, revenue was $982M (+33% year on year) and net income −$416M. Its largest product in Q2 2026 was Oncology at $219M, 65% of the disclosed total, well ahead of Biopharma Data at 18%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $335M | $232M | +44% |
| Gross profit | $219M | $151M | +45% |
| Operating income | −$129M | −$106M | n/a |
| Net income | −$120M | −$100M | n/a |
| Diluted EPS | −$0.90 | −$0.80 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Oncology | $219M | 65% |
| Biopharma Data | $61M | 18% |
| Screening | $53M | 16% |
| Licensing Other | $2.1M | 0.6% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $335.0M (+11%)
Screening grew +257% year on yearLicensing Other -20% year on year
Segment Latestquarter on quarteryear on year
- Oncology$219.1M$219.1Mquarter on quarter +6.9%year on year +38%+6.9%+38%
- Biopharma Data$60.9M$60.9Mquarter on quarter +15%year on year +8.8%+15%+8.8%
- Screening$52.9M$52.9Mquarter on quarter +27%year on year +257%+27%+257%
- Licensing Other$2.1M$2.1Mquarter on quarter -3.9%year on year -20%-3.9%-20%
Diagnostics & Research
Ranks #18 of 21 by RyuScore